Intellia Therapeutics, Inc.
NTLA
$11.91
$0.080.68%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -49.10% | -34.62% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -49.10% | -34.62% | |||
| Cost of Revenue | 2.30% | 9.66% | |||
| Gross Profit | -14.08% | -29.80% | |||
| SG&A Expenses | 8.56% | -27.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.19% | -5.05% | |||
| Operating Income | -12.16% | -1.85% | |||
| Income Before Tax | -10.81% | -0.46% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -10.81% | -0.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.81% | -0.46% | |||
| EBIT | -12.16% | -1.85% | |||
| EBITDA | -12.56% | -2.08% | |||
| EPS Basic | 1.63% | 1.72% | |||
| Normalized Basic EPS | 0.40% | -1.11% | |||
| EPS Diluted | 1.63% | 1.72% | |||
| Normalized Diluted EPS | 0.40% | -1.11% | |||
| Average Basic Shares Outstanding | 12.65% | 2.22% | |||
| Average Diluted Shares Outstanding | 12.65% | 2.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||